TISSUE SCIENCE LABORATORIES LIMITED

1. TISSUE SCIENCE LABORATORIES LIMITED 2009-09-28 → present
2. TISSUE SCIENCE LABORATORIES PLC 1999-06-04 → 2009-09-28
3. TISSLAB PLC 1999-01-07 → 1999-06-04

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Standalone (parent only)

Auditor

PricewaterhouseCoopers LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“Tissue Science Laboratories Limited has obtained a letter of support from a Group company, Medtronic Plc, confirming that it is their intention to provide financial support to the Company to allow it to meet its liabilities as they become due for a period of not less than 12 months from the date on which the financial statements of the Company for the period ended 25 April 2025 are approved by the director of the Company. The director has confirmed that Medtronic Plc has the financial resources and legal ability to provide Tissue Science Laboratories Limited with support.”

Significant events

• “After the end of the financial period ended 25 April 2025, it has been brought to the attention of the directors that the Company had received the benefit of net operating losses ("NOLs") transferred from another Group entity without payment of any monetary consideration (i.e. assets with an intrinsic value were transferred by the Group entity for which the Group entity was not compensated). The transfer was made at a time when the transferring entity did not have sufficient distributable reserves to support the distributions at the time they were made, which was not in compliance with the requirements of the Companies Act 2006. To address this issue, the directors have developed a remediation plan to be implemented during the financial period ending on 24 April 2026, pursuant to which the Company will make a payment to the transferring entity equal to the fair value of the NOLs received (determined to be the tax value of the NOLs transferred). The total amount expected to be paid by the Company is £482k. This payment will regularise the transaction in accordance with fair value principles and eliminate any deemed distribution considerations.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

3

last 12 months

Capital events

0

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -22.2%

  £63,000 → £49,000

• Net assets

  +6.7%

  £25,671,000 → £27,389,000

• Employees

  —

  Not reported

• Operating profit

  -90.4%

  £3,747,000 → £359,000

• Profit before tax

  -66.4%

  £5,110,000 → £1,718,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers